New therapies, evidence, and guidance in hepatitis C management: Expert practices and insights from an educational symposium at the AMCP 27th Annual Meeting and Expo

Journal of Managed Care Pharmacy

Volumn 21, Issue , 2015, Pages S1-S15

  Terrault, Norah ^a   Monto, Alex ^a   Stinchon, Michael R ^b   Rusie, Erica ^c   Moreo, Kathleen ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b AETNA   (United States)

^c PRIME Education   (United States)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; LEDIPASVIR PLUS SOFOSBUVIR; OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; PEGINTERFERON; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR;

ANTIVIRAL THERAPY; ARTICLE; CLINICAL PRACTICE; CONTINUING EDUCATION; DECOMPENSATED LIVER CIRRHOSIS; EVIDENCE BASED MEDICINE; HEALTH CARE COST; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 3; HUMAN; LIVER BIOPSY; LIVER FIBROSIS; MEDICAL DECISION MAKING; PATIENT ASSESSMENT; PATIENT COMPLIANCE; PATIENT EDUCATION; PRACTICE GUIDELINE; TREATMENT DURATION; TREATMENT INDICATION; VIRUS LOAD; COMPLICATION; DRUG APPROVAL; HEALTH INSURANCE; LIVER CIRRHOSIS; QUALITY OF LIFE; VIROLOGY;

ANTIVIRAL AGENTS; DRUG APPROVAL; HEPATITIS C; HUMANS; LIVER CIRRHOSIS; MANAGED CARE PROGRAMS; QUALITY OF LIFE; VIRAL LOAD;

EID: 84947558063     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2015.21.9.s1     Document Type: Article

References (78)

1. Smith-Palmer J, Cerri K, Valentine W. Achieving sustained virologic response in hepatitis C: a systematic review of the clinical, economic and quality of life benefits. BMC Infect Dis. 2015;15(1):19. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4299677/pdf/12879_2015_ Article_748.pdf. Accessed July 17, 2015.
2. American Association for the Study of Liver Diseases, Infectious Diseases Society of America, International Antiviral Society-USA. HCV guidance: recommendations for testing, managing, and treating HCV. June 25, 2015. Available at: www.hcvguidelines.org. Accessed July 16, 2015.
3. Everhart JE, Wright EC, Goodman ZD, et al. Prognostic value of Ishak fibrosis stage: findings from the hepatitis C antiviral long-term treatment against cirrhosis trial. Hepatology. 2010;51(2):585-94. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3814134/pdf/nihms502635.pdf. Accessed July 17, 2015.
4. Regev A, Berho M, Jeffers LJ, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol. 2002;97(10):2614-18.
5. [No authors listed]. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. Hepatology. 1994;20(1 Pt 1):15-20.
6. Westin J, Lagging LM, Wejstål R, Norkrans G, Dhillon AP. Interobserver study of liver histopathology using the Ishak score in patients with chronic hepatitis C virus infection. Liver. 1999;19(3):183-87.
7. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology. 2003;38(6):1449-57. Available at: http://onlinelibrary.wiley.com/doi/10.1016/j.hep.2003.09.022/epdf. Accessed July 17, 2015.
8. Thampanitchawong P, Piratvisuth T. Liver biopsy: complications and risk factors. World J Gastroenterol. 1999;5(4):301-04. Available at: http://www. wjgnet.com/1007-9327/5/301.pdf. Accessed July 17, 2015.
9. Robert M, Sofair AN, Thomas A, et al. A comparison of hepatopathologists' and community pathologists' review of liver biopsy specimens from patients with hepatitis C. Clin Gastroenterol Hepatol. 2009;7(3):335-38. Available at: http://www.cghjournal.org/article/S1542-3565(08)01231-7/pdf. Accessed July 17, 2015.
10. Rockey DC, Caldwell SH, Goodman ZD, et al. Liver biopsy. Hepatology. 2009;49(3):1017-44. Available at: http://onlinelibrary.wiley.com/doi/10.1002/hep.22742/epdf. Accessed July 17, 2015.
11. Filingeri V, Sforza D, Tisone G. Complications and risk factors of a large series of percutaneous liver biopsies in patients with liver transplantation or liver disease. Eur Rev Med Pharmacol Sci. 2015;19(9):1621-29. Available at: http://www.europeanreview.org/wp/wp-content/uploads/1621-1629.pdf. Accessed July 17, 2015.
12. Dohan A, Guerrache Y, Dautry R, et al. Major complications due to transjugular liver biopsy: incidence, management and outcome. Diagn Interv Imaging. 2015;96(6):571-77.
13. West J, Card TR. Reduced mortality rates following elective percutaneous liver biopsies. Gastroenterology. 2010;139(4):1230-37. Available at: http://www.gastrojournal.org/article/S0016-5085(10)00874-7/pdf. Accessed July 17, 2015.
14. U.S. Food and Drug Administration. Letter to Dipu Ghosh, Hepatiq CEO from Robert A. Ochs, Acting Director, Division of Radiological Health. Re: Hepatiq 510k. December 17, 2014. Available at: http://www.accessdata.fda. gov/cdrh_docs/pdf14/K142891.pdf. Accessed August 10, 2015.
15. Tapper EB, Afdhal NH. Is 3 the new 1: perspectives on virology, natural history and treatment for hepatitis C genotype 3. J Viral Hepat. 2013;20(10):669-77.
16. Stebbing J, Farouk L, Panos G, et al. A meta-analysis of transient elastography for the detection of hepatic fibrosis. J Clin Gastroenterol. 2010;44(3):214-19. Available at: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0030019. Accessed July 11, 2015.
17. Poynard T, de Ledinghen V, Zarski JP, et al. Relative performances of FibroTest, Fibroscan, and biopsy for the assessment of the stage of liver fibrosis in patients with chronic hepatitis C: a step toward the truth in the absence of a gold standard. J Hepatol. 2012;56(3):541-48.
18. Calvaruso V, Camma C, Di Marco V, et al. Fibrosis staging in chronic hepatitis C: analysis of discordance between transient elastography and liver biopsy. J Viral Hepat. 2010;17(7):469-74.
19. Cobbold JF, Crossey MM, Colman P, et al. Optimal combinations of ultrasound-based and serum markers of disease severity in patients with chronic hepatitis C. J Viral Hepat. 2010;17(8):537-45.
20. Talwalkar JA, Kurtz DM, Schoenleber SJ, et al. Ultrasound-based transient elastography for the detection of hepatic fibrosis: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2007;5(10):1214-20. Available at: http://www.cghjournal.org/article/S1542-3565(07)00753-7/pdf. Accessed July 11, 2015.
21. Berzigotti A, De Gottardi A, Vukotic R, et al. Effect of meal ingestion on liver stiffness in patients with cirrhosis and portal hypertension. PLoS One. 2013;8(3):e58742. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3592829/pdf/pone.0058742.pdf. Accessed July 11, 2015.
22. Fraquelli M, Rigamonti C, Casazza G, et al. Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease. Gut. 2007;56(7):968-73. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1994385/pdf/968.pdf. Accessed July 11, 2015.
23. Wong GL. Update of liver fibrosis and steatosis with transient elastography (Fibroscan). Gastroenterol Rep (Oxf). 2013;1(1):19-26. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3941434/pdf/got007.pdf. Accessed July 11, 2015.
24. Castera L, Sebastiani G, Le Bail B, et al. Prospective comparison of two algorithms combining non-invasive methods for staging liver fibrosis in chronic hepatitis C. J Hepatol. 2010;52(2):191-98.
25. Arena U, Lupsor Platon M, Stasi C, et al. Liver stiffness is influenced by a standardized meal in patients with chronic hepatitis C virus at different stages of fibrotic evolution. Hepatology. 2013;58(1):65-72. Available at: http://onlinelibrary.wiley.com/doi/10.1002/hep.26343/epdf. Accessed July 17, 2015.
26. Wong GL, Wong VW, Choi PC, et al. Assessment of fibrosis by transient elastography compared with liver biopsy and morphometry in chronic liver diseases. Clin Gastroenterol Hepatol. 2008;6(9):1027-35. Available at: http://www. cghjournal.org/article/S1542-3565(08)00200-0/pdf. Accessed July 17, 2015.
27. Chou R, Wasson N. Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection: a systematic review. Ann Intern Med. 2013;158(11):807-20. Available at: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0056949. Accessed July 17, 2015.
28. Nguyen D, Talwalkar JA. Noninvasive assessment of liver fibrosis. Hepatology. 2011;53(6):2107-10. Available at: http://onlinelibrary.wiley.com/doi/10.1002/hep.24401/pdf. Accessed July 17, 2015.
29. Younossi ZM, Stepanova M, Afdhal N, et al. Improvement of health-related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir. J Hepatol. 2015;63(2):337-45.
30. Younossi ZM, Stepanova M, Nader F, Lam B, Hunt S. The patient's journey with chronic hepatitis C from interferon plus ribavirin to interferonand ribavirin-free regimens: a study of health-related quality of life. Aliment Pharmacol Ther. 2015;42(3):286-95.
31. Yeung MW, Young J, Moodie E, et al. Changes in quality of life, healthcare use, and substance use in HIV/hepatitis C coinfected patients after hepatitis C therapy: a prospective cohort study. HIV Clin Trials. 2015;16(3):100-10.
32. Jezequel C, Bardou-Jacquet E, Desille E. Survival of patients infected by chronic hepatitis C and F0F1 fibrosis at baseline after a 15 year follow-up. Poster presented at: 50th Annual Meeting of the European Association for the Study of the Liver (EASL); April 22-26, 2015; Vienna, Austria. [Abstract P0709]
33. Øvrehus AL, Blach S, Christensen PB. Impact of prioritizing treatment in a high resource setting-minimizing the burden of HCV related disease in 15 years. Poster presented at: 50th Annual Meeting of the European Association for the Study of the Liver (EASL); April 22-26, 2015; Vienna, Austria. [Abstract P0714]
34. Zahnd C, Salazar-Vizcaya LP, Dufour JF, Team SHaHCCS. Impact of deferring HCV treatment on liver-related events in HIV+ patients. Poster presented at: 2015 Conference on Retroviruses and Opportunistic Infections; February 23-24, 2015; Seattle, Washington. [Abstract 150]
35. McComb JS, Tonnu-MiHara I, Matsuds T. Can hepatitis C treatment be safely delayed? Evidence from the Veterans Administration Healthcare System. Poster presented at: 50th Annual Meeting of the European Association for the Study of the Liver (EASL); April 22-26, 2015; Vienna, Austria. [Abstract O005]
36. Martin NK, Hickman M, Hutchinson SJ, et al. Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy. Clin Infect Dis. 2013;57(Suppl 2):S39-45.
37. Martin NK, Hickman M, Hutchinson SJ, Goldberg DJ, Vickerman P. Hepatitis C virus treatment for prevention among people who inject drugs: modeling treatment scale-up in the age of direct-acting antivirals. Hepatology. 2013;58 (5):1598-609. Available at: http://www.ncbi.nlm.nih. gov/pmc/articles/PMC3933734/. Accessed July 17, 2015.
38. Durier N, Nguyen C, White LJ. Treatment of hepatitis C as prevention: a modeling case study in Vietnam. PLoS One. 2012;7(4):e34548. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3325261/pdf/pone.0034548. pdf. Accessed July 17, 2015.
39. Younossi ZM, Park H, Saab S, Ahmed A, Dieterich D, Gordon SC. Costeffectiveness of all-oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection. Aliment Pharmacol Ther. 2015;41(6):544-63.
40. Canary LA, Klevens RM, Holmberg SD. Limited access to new hepatitis C virus treatment under state Medicaid programs. Ann Intern Med. 2015 Jun 30. [Epub ahead of print]
41. Barua S, Greenwald R, Grebely J, et al. Restrictions for Medicaid reimbursement of sofosbuvir for the treatment of hepatitis C virus infection in the United States. Ann Intern Med. 2015 Jun 30. [Epub ahead of print]
42. HARVONI (ledipasvir and sofosbuvir) tablets, for oral use. Gilead Sciences, Inc. Revised October 2014. Available at: http://www.accessdata.fda. gov/drugsatfda_docs/label/2014/205834s000lbl.pdf. Accessed July 31, 2015.
43. Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014;370(20):1879-88. Available at: http://www.nejm.org/doi/pdf/10.1056/NEJMoa1402355. Accessed July 17, 2015.
44. Barreiro P, Labarga P, Fernandez-Montero JV, et al. Longitudinal changes in viral RNA concentration in patients with chronic hepatitis C and/or HIV infection in the absence of antiviral therapy. J Clin Virol. 2013;58(2):391-95.
45. Kuramoto IK, Moriya T, Schoening V, Holland PV. Fluctuation of serum HCV-RNA levels in untreated blood donors with chronic hepatitis C virus infection. J Viral Hepat. 2002;9(1):36-42.
46. Fanning L, Kenny-Walsh E, Levis J, et al. Natural fluctuations of hepatitis C viral load in a homogeneous patient population: a prospective study. Hepatology. 2000;31(1):225-29. Available at: http://onlinelibrary.wiley.com/doi/10.1002/hep.510310133/epdf. Accessed July 17, 2015.
47. Reddy KR, Bourliere M, Sulkowski M, et al. Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: an integrated safety and efficacy analysis. Hepatology. 2015;62(1):79-86.
48. Bourliere M, Bronowicki JP, de Ledinghen V, et al. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS). Lancet Infect Dis. 2015;15(4):397-404.
49. Feld JJ, Kowdley KV, Coakley E, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370(17):1594-603. Available at: http://www.nejm.org/doi/pdf/10.1056/NEJMoa1315722. Accessed July 17, 2015.
50. Ferenci P, Bernstein D, Lalezari J, et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med. 2014;370(21):1983-92.Available at: http://www.nejm.org/doi/pdf/10.1056/NEJMoa1402338. Accessed July 17, 2015.
51. Andreone P, Colombo MG, Enejosa JV, et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterology. 2014;147(2):359-65.e1. Available at: http://www.gastrojournal.org/article/S0016-5085(14)00603-9/pdf. Accessed July 17, 2015.
52. Poordad F, Agarwal K, Younes Z, Cohen D, Xie W, Podsadecki T. Low relapse rate leads to high concordance of sustained virologic response (SVR) at 12 weeks with SVR at 24 weeks after treatment with ABT-450/ritonavir, ombitasvir, and dasabuvir plus ribavirin in subjects with chronic hepatitis C virus genotype 1 infection in the AVIATOR study. Clin Infect Dis. 2015;60(4):608-10.
53. Zeuzem S, Jacobson IM, Baykal T, et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370(17):1604-14. Available at: http://www.nejm.org/doi/pdf/10.1056/NEJMoa1401561. Accessed July 17, 2015.
54. Poordad F, Hezode C, Trinh R, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med. 2014;370(21):1973-82. Available at: http://www.nejm.org/doi/pdf/10.1056/NEJMoa1402869. Accessed July 17, 2015.
55. Feld JJ, Moreno C, Trinh R, et al. Turquoise-III: safety and efficacy of 12-week ribavirin-free treatment for patients with HCV genotype 1b and cirrhosis. Poster presented at: 15th Annual International Symposium on Viral Hepatitis and Liver Diseases; June 26-28, 2015; Berlin, Germany. [Abstract P226]
56. Ampuero J, Romero-Gomez M, Reddy KR. Review article: HCV genotype 3-the new treatment challenge. Aliment Pharmacol Ther. 2014;39(7):686-98.
57. Zeuzem S, Dusheiko GM, Salupere R, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med. 2014;370(21):1993-2001. Available at: http://www.nejm.org/doi/pdf/10.1056/NEJMoa1316145. Accessed July 17, 2015.
58. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368(20):1878-87. Available at: http://www.nejm.org/doi/pdf/10.1056/NEJMoa1214853. Accessed July 17, 2015.
59. Gane E, Hyland R, Di A. Once-daily sofosbuvir with GS-5816 for 8 weeks with or without ribavirin in patients with HCV genotype 3 without cirrhosis result in high rates of SVR12: the ELECTRON-2 Study. Poster presented at: The 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD); November 7-12, 2014; Boston, MA.
60. Kanwal F, Kramer JR, Ilyas J, Duan Z, El-Serag HB. HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of U.S. Veterans with HCV. Hepatology. 2014;60(1):98-105. Available at: http://onlinelibrary.wiley.com/doi/10.1002/hep.27095/epdf. Accessed July 17, 2015.
61. Abenavoli L, Masarone M, Peta V, et al. Insulin resistance and liver steatosis in chronic hepatitis C infection genotype 3. World J Gastroenterol. 2014;20(41):15233-40. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223256/pdf/WJG-20-15233.pdf. Accessed July 17, 2015.
62. Foster GR, Pianko S, Cooper C. Sofosbuvir + peginterferon/ribavirin for 12 weeks vs sofosbuvir + ribavirin for 16 or 24 weeks in genotype 3 HCV infected patients and treatment-experienced cirrhotic patients with genotype 2 HCV: the BOSON study. Poster presented at: 50th Annual Meeting of the European Association for the Study of the Liver (EASL); April 22-26, 2015; Vienna, Austria. [Abstract L05]
63. Gane E, Hyland R, An D, Evguenia S. High efficacy of LDV/SOF regimens for 12 weeks for patients with HCV genotype 3 or 6 infection. Poster presented at: 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). November 7-12, 2014; Boston, MA.
64. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370(20):1889-98. Available at: http://www.nejm.org/doi/pdf/10.1056/NEJMoa1402454. Accessed July 17, 2015.
65. Poordad F, Sievert W, Mollison L, et al. Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection. JAMA. 2015;313(17):1728-35.
66. Nelson DR, Cooper JN, Lalezari JP, et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology. 2015;61(4):1127-35. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4409820/pdf/hep0061-1127.pdf. Accessed July 17, 2015.
67. Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med. 2013;368(20):1867-77.
68. Manns MP, Forns X, Samuel D, et al. Ledipasvir/sofosbuvir with ribavirin is safe and efficacious in decompensated and post liver transplantation patients with HCV infection: preliminary results of the Prospective SOLAR 2 Trial. Poster presented at: 50th Annual Meeting of the European Association for the Study of the Liver (EASL); April 22-26, 2015; Vienna, Austria. [Abstract G02]
69. Jacobson I, Poordad F, Firpi-Morell R, et al. Efficacy and safety af grazoprevir and elbasvir in hepatitis C genotype 1-infected patients with Child- Pugh Class B cirrhosis (C-SALT Part A). Poster presented at: 50th Annual Meeting of the European Association for the Study of the Liver (EASL); April 22-26, 2015; Vienna, Austria. [Abstract O008]
70. Ruiz I, Feray C, Pawlotsky JM, Hezode C. Patient with decompensated hepatitis C virus-related cirrhosis delisted for liver transplantation after successful sofosbuvir-based treatment. Liver Transpl. 2015;21(3):408-09.
71. REBETOL (ribavirin USP) capsules, for oral use and oral solution. Merck & Co. Inc. Revised May 2015. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020903s053,021546s009lbl.pdf. Accessed July 17, 2015.
72. Roth D, Nelson DR, Bruchfeld A. C-SURFER: grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease. Poster presented at: 50th Annual Meeting of the European Association for the Study of the Liver (EASL); April 22-26, 2015; Vienna, Austria. [Abstract LP02]
73. Gane E, Robson RA, Bonacini M. Safety, Antiviral efficacy, and pharmacokinetics of sofosbuvir in patients with severe renal impairment. Poster presented at: 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD); November 7-12, 2014; Boston, MA. [Abstract 966]
74. Wyles D, Mangia A, Cheng W, et al. Long-term persistence of HCV variants after treatment with NS5A inhibitor ledipasvir. Poster presented at: 50th Annual Meeting of the European Association for the Study of the Liver (EASL); April 22-26, 2015; Vienna, Austria. [Abstract O059]
75. Krishnan P, Tripathi R, Schnell G, et al. Long-term follow-up of treatment- emergent resistance-associated variants in NS3, NS5A and NS5B with paritaprevir/r-, ombitasvir- and dasabuvir-based regimens. Poster presented at: 50th Annual Meeting of the European Association for the Study of the Liver (EASL); April 22-26, 2015; Vienna, Austria. [Abstract O057]
76. Townsed K, Petersen T, Gordon L, et al. Effect of HIV co-infection on adherence to a 12-week regimen of HCV therapy with ledipasvir/sofosbuvir. Poster presented at: 2015 Conference on Retroviruses and Opportunistic Infections; February 23-26, 2015; Seattle, WA. [Abstract 692]
77. Osinusi A, Townsend K, Kohli A, et al. Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection. JAMA. 2015;313(12):1232-39.
78. Weiss JJ, Bhatti L, Dieterich DT, et al. Hepatitis C patients' self-reported adherence to treatment with pegylated interferon and ribavirin. Aliment Pharmacol Ther. 2008;28(3):289-93. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2891196/pdf/nihms80049.pdf. Accessed July 17, 2015.